These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Pulmonary granulomata. A complication of intravesical administration of bacillus Calmette-Guerin for superficial bladder carcinoma. Smith RL; Alexander RF; Aranda CP Cancer; 1993 Mar; 71(5):1846-7. PubMed ID: 8448747 [TBL] [Abstract][Full Text] [Related]
27. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. Haaff EO; Dresner SM; Ratliff TL; Catalona WJ J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438 [TBL] [Abstract][Full Text] [Related]
28. [Granulomatous interstitial nephritis with acute renal insufficiency, a potential complication of intravesicular bcg therapy]. Binaut R; Bridoux F; Provôt F; Daniel N; Fleury D; Mougenot B; Vanhille P Nephrologie; 1997; 18(5):187-91. PubMed ID: 9424596 [TBL] [Abstract][Full Text] [Related]
29. [Severely contracted bladder following intravesical bacillus Calmette-Guérin therapy]. Yoshimura K; Saiki S; Kuroda M; Kiyohara H; Kotake T Nihon Hinyokika Gakkai Zasshi; 1988 Nov; 79(11):1848-51. PubMed ID: 3216568 [No Abstract] [Full Text] [Related]
30. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041 [TBL] [Abstract][Full Text] [Related]
31. Granulomatous pneumonitis following intravesical BCG. What therapy is needed? LeMense GP; Strange C Chest; 1994 Nov; 106(5):1624-6. PubMed ID: 7956439 [TBL] [Abstract][Full Text] [Related]
32. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer. Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172 [TBL] [Abstract][Full Text] [Related]
33. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051 [TBL] [Abstract][Full Text] [Related]
34. [Granulomatous hepatitis and sepsis secondary to intravesical instillation of bacillus Calmette-Guérin]. Garmilla-Ezquerra P; Martínez-De Las Cuevas G; Hernández-Hernández JL Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):656-7. PubMed ID: 22683174 [No Abstract] [Full Text] [Related]
35. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer. Brosman SA; Lamm DL J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197 [TBL] [Abstract][Full Text] [Related]
36. Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder. Spirnak JP; Lubke WL; Thompson IM; Lopez M Urology; 1993 Jul; 42(1):89-92. PubMed ID: 8328131 [TBL] [Abstract][Full Text] [Related]